

# Tetanus (Infectious Disease) - Drugs In Development, 2021

<https://marketpublishers.com/r/TD80E29BF1F6EN.html>

Date: July 2021

Pages: 98

Price: US\$ 2,000.00 (Single User License)

ID: TD80E29BF1F6EN

## Abstracts

Tetanus (Infectious Disease) - Drugs In Development, 2021

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Tetanus - Drugs In Development, 2021, provides an overview of the Tetanus (Infectious Disease) pipeline landscape.

Tetanus is a serious illness caused by Clostridium bacteria. Signs and symptoms of tetanus include spasms and stiffness in jaw muscles, difficulty swallowing, stiffness of abdominal muscles, fever, sweating, elevated blood pressure and rapid heart rate. The predisposing factors include burns, surgical wounds, ear infections, swelling around the injury and infected foot ulcers. Treatment includes antibiotics, sedatives and beta blockers.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Tetanus - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Tetanus (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Tetanus (Infectious Disease) pipeline guide also reviews of key players involved in

therapeutic development for Tetanus and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 11, 5, 11, 1, 13, 2 and 1 respectively. Similarly, the Universities portfolio in Phase II and Discovery stages comprises 1 and 1 molecules, respectively.

Tetanus (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Tetanus (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Tetanus (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Tetanus (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Tetanus (Infectious Disease) therapeutics based

on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Tetanus (Infectious Disease)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Tetanus (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Tetanus (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

- Introduction
- Global Markets Direct Report Coverage
- Tetanus - Overview
- Tetanus - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Tetanus - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Tetanus - Companies Involved in Therapeutics Development
- AIM Vaccine Co Ltd
- Beijing Minhai Biotechnology Co Ltd
- Beijing Tiantan Biological Products Co Ltd
- Biken Co Ltd
- Biological E Ltd
- BioNet-Asia Co Ltd
- Boryung Pharmaceutical Co Ltd
- Cadila Healthcare Ltd
- CanSino Biologics Inc
- Changchun Bcht Biotechnology Co Ltd
- Chengdu Kanghua Biological Products Co Ltd
- Chongqing Zhifei Biological Products Co Ltd
- GC Pharma
- GlaxoSmithKline Plc
- KM Biologics Co Ltd
- LG Chem Ltd
- Novo Medi Sciences Pvt Ltd
- NTxBio LLC
- Olymvax Biopharmaceuticals Inc
- Panacea Biotec Ltd
- Sanofi
- Seasons Healthcare Ltd

Serum Institute of India Pvt Ltd

Shantha Biotechnics Pvt Ltd

Sichuan ZehaTimes Pharmaceutical Co Ltd

Stablepharma Ltd

VaxForm LLC

Yisheng Biopharma Co Ltd

Yuxi Jiuzhou Biological Technology Co Ltd

Zhuhai Trinomab Biotechnology Co Ltd

Tetanus - Drug Profiles

(diphtheria + Haemophilus influenza [serotype B] + hepatitis B + pertussis

(acellular,adsorbed) + rotavirus + tetanus) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + Haemophilus influenza [serotype B] + hepatitis B + pertussis + tetanus)

(pentavalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + haemophilus influenza [serotype B] + meningococcal + pertussis

(acellular) + tetanus) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + Haemophilus influenza [serotype B] + pertussis (acellular) + polio +

tetanus) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + haemophilus influenza [serotype B] + pertussis (acellular) + poliomyelitis +

tetanus) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + Haemophilus influenza [serotype B] + pertussis (acellular) + tetanus)

(tetravalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] + pertussis (whole cell) + poliomyelitis + tetanus) (heptavalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + tetanus) (pentavalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole cell) + polio + tetanus)(pentavalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + haemophilus influenzae [serotype B] + pertussis (whole cell) + tetanus) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + pertussis (acellular) + tetanus) vaccine 1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + pertussis (acellular) + tetanus) vaccine 1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + pertussis (acellular) + tetanus) vaccine 2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + pertussis (acellular) + tetanus) vaccine 2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + pertussis (whole cell) + tetanus) (trivalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + pertussis (whole cell) + tetanus) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + pertussis + poliomyelitis + tetanus) vaccine - Drug Profile

Product Description

Mechanism Of Action

**R&D Progress**

(diphtheria + pertussis + tetanus) (acellular, adsorbed) vaccine - Drug Profile

Product Description

Mechanism Of Action

**R&D Progress**

(diphtheria + pertussis + tetanus) vaccine - Drug Profile

Product Description

Mechanism Of Action

**R&D Progress**

(diphtheria + pertussis + tetanus) vaccine - Drug Profile

Product Description

Mechanism Of Action

**R&D Progress**

(diphtheria + tetanus + pertussis (acellular) + haemophilus influenzae [serotype B])  
vaccine - Drug Profile

Product Description

Mechanism Of Action

**R&D Progress**

(diphtheria + tetanus + pertussis (acellular) + poliomyelitis) vaccine - Drug Profile

Product Description

Mechanism Of Action

**R&D Progress**

(diphtheria + tetanus + pertussis (acellular)) vaccine 1 - Drug Profile

Product Description

Mechanism Of Action

**R&D Progress**

(diphtheria + tetanus + pertussis + poliomyelitis + haemophilus influenzae [serotype B])  
vaccine - Drug Profile

Product Description

Mechanism Of Action

**R&D Progress**

(diphtheria + tetanus) vaccine - Drug Profile

Product Description

Mechanism Of Action

**R&D Progress**

Adacel plus - Drug Profile

Product Description

Mechanism Of Action

**R&D Progress**



**Antibody for Tetanus - Drug Profile**

Product Description

Mechanism Of Action

R&amp;D Progress

**B-1004 - Drug Profile**

Product Description

Mechanism Of Action

R&amp;D Progress

**BK-1310 - Drug Profile**

Product Description

Mechanism Of Action

R&amp;D Progress

**DTcP vaccine - Drug Profile**

Product Description

Mechanism Of Action

R&amp;D Progress

**GC-3111A - Drug Profile**

Product Description

Mechanism Of Action

R&amp;D Progress

**KD-370 - Drug Profile**

Product Description

Mechanism Of Action

R&amp;D Progress

**LBVD - Drug Profile**

Product Description

Mechanism Of Action

R&amp;D Progress

**NTXV-01 - Drug Profile**

Product Description

Mechanism Of Action

R&amp;D Progress

**tetanus vaccine - Drug Profile**

Product Description

Mechanism Of Action

R&amp;D Progress

**tetanus vaccine - Drug Profile**

Product Description

Mechanism Of Action

R&D Progress

tetanus vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tetanus vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tetanus vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tetanus vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TNM-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Tetanus - Dormant Projects

Tetanus - Discontinued Products

Tetanus - Product Development Milestones

Featured News & Press Releases

Mar 11, 2019: LG Chem gets \$33.4 mil. from Gates Foundation for vaccine development

Aug 02, 2016: CanSino submits a clinical trial application for the component DTP diphtheria tetanus pertussis combo vaccine (adults, teenagers and children above 6 years Old)

Sep 01, 2015: Commercialisation of a world changing invention for the stabilisation and delivery of vaccines

Nov 24, 2014: CanSinotech submitted CTA of "Diphtheria and Tetanus Toxoids and Component Pertussis Vaccine Adsorbed" to CFDA

Appendix

Methodology

Coverage

Secondary Research

Primary Research

[Expert Panel Validation](#)

[Contact Us](#)

[Disclaimer](#)

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Tetanus, 2021  
Number of Products under Development by Companies, 2021  
Number of Products under Development by Companies, 2021 (Contd..1)  
Number of Products under Development by Universities/Institutes, 2021  
Products under Development by Companies, 2021  
Products under Development by Companies, 2021 (Contd..1)  
Products under Development by Companies, 2021 (Contd..2)  
Products under Development by Universities/Institutes, 2021  
Number of Products by Stage and Target, 2021  
Number of Products by Stage and Mechanism of Action, 2021  
Number of Products by Stage and Route of Administration, 2021  
Number of Products by Stage and Molecule Type, 2021  
Tetanus - Pipeline by AIM Vaccine Co Ltd, 2021  
Tetanus - Pipeline by Beijing Minhai Biotechnology Co Ltd, 2021  
Tetanus - Pipeline by Beijing Tiantan Biological Products Co Ltd, 2021  
Tetanus - Pipeline by Biken Co Ltd, 2021  
Tetanus - Pipeline by Biological E Ltd, 2021  
Tetanus - Pipeline by BioNet-Asia Co Ltd, 2021  
Tetanus - Pipeline by Boryung Pharmaceutical Co Ltd, 2021  
Tetanus - Pipeline by Cadila Healthcare Ltd, 2021  
Tetanus - Pipeline by CanSino Biologics Inc, 2021  
Tetanus - Pipeline by Changchun Bcht Biotechnology Co Ltd, 2021  
Tetanus - Pipeline by Chengdu Kanghua Biological Products Co Ltd, 2021  
Tetanus - Pipeline by Chongqing Zhifei Biological Products Co Ltd, 2021  
Tetanus - Pipeline by GC Pharma, 2021  
Tetanus - Pipeline by GlaxoSmithKline Plc, 2021  
Tetanus - Pipeline by KM Biologics Co Ltd, 2021  
Tetanus - Pipeline by LG Chem Ltd, 2021  
Tetanus - Pipeline by Novo Medi Sciences Pvt Ltd, 2021  
Tetanus - Pipeline by NTxBio LLC, 2021  
Tetanus - Pipeline by Olymvax Biopharmaceuticals Inc, 2021  
Tetanus - Pipeline by Panacea Biotec Ltd, 2021  
Tetanus - Pipeline by Sanofi, 2021  
Tetanus - Pipeline by Seasons Healthcare Ltd, 2021  
Tetanus - Pipeline by Serum Institute of India Pvt Ltd, 2021

Tetanus - Pipeline by Shantha Biotechnics Pvt Ltd, 2021  
Tetanus - Pipeline by Sichuan ZehaTimes Pharmaceutical Co Ltd, 2021  
Tetanus - Pipeline by Stablepharma Ltd, 2021  
Tetanus - Pipeline by VaxForm LLC, 2021  
Tetanus - Pipeline by Yisheng Biopharma Co Ltd, 2021  
Tetanus - Pipeline by Yuxi Jiuzhou Biological Technology Co Ltd, 2021  
Tetanus - Pipeline by Zhuhai Trinomab Biotechnology Co Ltd, 2021  
Tetanus - Dormant Projects, 2021  
Tetanus - Dormant Projects, 2021 (Contd..1)  
Tetanus - Discontinued Products, 2021

## List Of Figures

### LIST OF FIGURES

- Number of Products under Development for Tetanus, 2021
- Number of Products under Development by Companies, 2021
- Number of Products under Development by Universities/Institutes, 2021
- Number of Products by Targets, 2021
- Number of Products by Stage and Targets, 2021
- Number of Products by Stage and Mechanism of Actions, 2021
- Number of Products by Routes of Administration, 2021
- Number of Products by Stage and Routes of Administration, 2021
- Number of Products by Molecule Types, 2021
- Number of Products by Stage and Top 10 Molecule Types, 2021

## I would like to order

Product name: Tetanus (Infectious Disease) - Drugs In Development, 2021

Product link: <https://marketpublishers.com/r/TD80E29BF1F6EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/TD80E29BF1F6EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970